Get access to our best features
Get access to our best features
Published

Nearly 2,000 drug manufacturing plants are overdue for FDA inspections after COVID delays, AP finds

  • Nearly 2,000 drug manufacturing plants have not been inspected since the COVID-19 pandemic began, according to an investigation by The Associated Press .
  • Over 340 overdue plants are located in India and China, which are key sources of drug ingredients for U.S. Prescriptions.
  • The FDA has experienced staff shortages, contributing to the backlog of uninspected plants, as noted by Rogers.
Insights by Ground AI
Does this summary seem wrong?
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 54% of the sources lean Left
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)